Akoya BioSciences Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results and Cut Its FY24 Revenue Guidance Below Estimates. Also, BTIG Maintained a Buy Rating on the Stock but Lowered Its Price Target From $9 to $6.
Akoya BioSciences Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results and Cut Its FY24 Revenue Guidance Below Estimates. Also, BTIG Maintained a Buy Rating on the Stock but Lowered Its Price Target From $9 to $6.
Akoya BioSciences的股價走低，此前該公司公佈的第一季度財務業績低於預期，並將24財年的收入預期下調至低於預期。此外，BTIG維持該股的買入評級，但將其目標股價從9美元下調至6美元。
Akoya BioSciences Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results and Cut Its FY24 Revenue Guidance Below Estimates. Also, BTIG Maintained a Buy Rating on the Stock but Lowered Its Price Target From $9 to $6.
Akoya BioSciences的股價走低，此前該公司公佈的第一季度財務業績低於預期，並將24財年的收入預期下調至低於預期。此外，BTIG維持該股的買入評級，但將其目標股價從9美元下調至6美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。